Literature DB >> 15662793

Long-term results of gamma knife surgery for growth hormone-producing pituitary adenoma: is the disease difficult to cure?

Tatsuya Kobayashi1, Yoshimasa Mori, Yukio Uchiyama, Yoshihsa Kida, Shigeru Fujitani.   

Abstract

OBJECT: The authors conducted a study to determine the long-term results of gamma knife surgery for residual or recurrent growth hormine (GH)-producing pituitary adenomas and to compare the results with those after treatment of other pituitary adenomas.
METHODS: The series consisted of 67 patients. The mean tumor diameter was 19.2 mm and volume was 5.4 cm3. The mean maximum dose was 35.3 Gy and the mean margin dose was 18.9 Gy. The mean follow-up duration was 63.3 months (range 13-142 months). The tumor resolution rate was 2%, the response rate 68.3%, and the control rate 100%. Growth hormone normalization (GH < 1.0 ng/ml) was found in 4.8%, nearly normal (< 2.0 ng/ml) in 11.9%, significantly decreased (< 5.0 ng/ml) in 23.8%, decreased in 21.4%, unchanged in 21.4%, and increased in 16.7%. Serum insulin-like growth factor (IGF)-1 was significantly decreased (IGF-1 < 400 ng/ml) in 40.7%, decreased in 29.6%, unchanged in 18.5%, and increased in 11.1%, which was almost parallel to the GH changes.
CONCLUSIONS: Gamma knife surgery was effective and safe for the control of tumors; however, normalization of GH and IGF-1 secretion was difficult to achieve in cases with large tumors and low-dose radiation. Gamma knife radiosurgery is thus indicated for small tumors after surgery or medication therapy when a relatively high-dose radiation is required.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15662793     DOI: 10.3171/jns.2005.102.s_supplement.0119

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  17 in total

Review 1.  Treatment of acromegaly: future.

Authors:  Ines Donangelo; Shlomo Melmed
Journal:  Endocrine       Date:  2005-10       Impact factor: 3.633

2.  Gamma knife radiosurgery for clinically persistent acromegaly.

Authors:  Xiaomin Liu; Hideyuki Kano; Douglas Kondziolka; Kyung-Jae Park; Aditya Iyer; Ajay Niranjan; John C Flickinger; L Dade Lunsford
Journal:  J Neurooncol       Date:  2012-04-26       Impact factor: 4.130

Review 3.  Radiation therapy in acromegaly.

Authors:  Helen A Shih; Jay S Loeffler
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

Review 4.  Treatment paradigms for pituitary adenomas: defining the roles of radiosurgery and radiation therapy.

Authors:  Dale Ding; Robert M Starke; Jason P Sheehan
Journal:  J Neurooncol       Date:  2014-05       Impact factor: 4.130

5.  Nelfinavir induces radiation sensitization in pituitary adenoma cells.

Authors:  Jing Zeng; Alfred P See; Khaled Aziz; Saravanan Thiyagarajan; Tarek Salih; Rajendra P Gajula; Michael Armour; Jillian Phallen; Stephanie Terezakis; Lawrence Kleinberg; Kristen Redmond; Russell K Hales; Roberto Salvatori; Alfredo Quinones-Hinojosa; Phuoc T Tran; Michael Lim
Journal:  Cancer Biol Ther       Date:  2011-10-01       Impact factor: 4.742

Review 6.  Updates in outcomes of stereotactic radiation therapy in acromegaly.

Authors:  Monica Livia Gheorghiu
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

Review 7.  Target delineation and optimal radiosurgical dose for pituitary tumors.

Authors:  Giuseppe Minniti; Mattia Falchetto Osti; Maximillian Niyazi
Journal:  Radiat Oncol       Date:  2016-10-11       Impact factor: 3.481

Review 8.  Cranial stereotactic radiosurgery: current status of the initial paradigm shifter.

Authors:  Jason P Sheehan; Chun-Po Yen; Cheng-Chia Lee; Jay S Loeffler
Journal:  J Clin Oncol       Date:  2014-08-11       Impact factor: 44.544

9.  Factors affecting early versus late remission in acromegaly following stereotactic radiosurgery.

Authors:  Mohana Rao Patibandla; Zhiyuan Xu; Jason P Sheehan
Journal:  J Neurooncol       Date:  2018-02-07       Impact factor: 4.130

Review 10.  Modern techniques for pituitary radiotherapy.

Authors:  G Minniti; D C Gilbert; M Brada
Journal:  Rev Endocr Metab Disord       Date:  2009-06       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.